Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome

被引：4

作者：

Lete, Inaki ^{[1
,2
]}

Martinez, Ainara ^{[1
]}

Lasaga, Irene ^{[1
]}

Centurion, Eva ^{[1
]}

Vesga, Amaia ^{[1
]}

机构：

[1] Araba Univ Hosp, Obstet & Gynaecol Clin Management Unit, Vitoria, Spain

[2] Araba Univ Hosp, Obstet & Gynaecol Clin Management Unit, Txagorritxu Campus, Vitoria 01009, Spain

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 2024年 / 40卷 / 01期

关键词：

Polycystic ovary syndrome; inositol; MYO/DCI ratio; HUMAN THECAL CELLS; GROWTH-FACTOR-I; FOLLICULAR-FLUID; OOCYTE QUALITY; THERAPEUTIC APPROACH; ANDROGEN PRODUCTION; GENE-PRODUCTS; IGF-II; MYOINOSITOL; WOMEN;

D O I：

10.1080/09513590.2023.2301554

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this article, we present a narrative review on the use of inositol in the treatment of polycystic ovary syndrome (PCOS). Of the different inositols that exist, only myo-inositol (MYO) and D-chiro inositol (DCI) have been studied in the treatment of PCOS. The results of the studies show that there is insufficient or controversial evidence to recommend the use of DCI alone, while MYO alone shows positive results and, above all, the MYO/DCI combination is effective when used at a ratio of at least 40:1, but there is enough rationale to further study ratios such as 66:1 to 100:1 as other possible effective combinations.

引用

页数：5

共 50 条

[1] The Rationale of the Myo-Inositol and D-Chiro-Inositol Combined Treatment for Polycystic Ovary Syndrome
Dinicola, Simona
Chiu, Tony T. Y.
Unfer, Vittorio
Carlomagno, Gianfranco
Bizzarri, Mariano
JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (10): : 1079 - 1092
[2] Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome
Unfer, Vittorio
Porcaro, Giuseppina
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (05) : 623 - 631
[3] Management of polycystic ovary syndrome among Indian women using myo-inositol and D-chiro-inositol
Vyas, Lila
Raiturker, Anagha Pai
Sud, Shilpi
Goyyal, Poonam
Abhyankarv, Mahesh
Ankar, Santosh Rev
Silki, Silki
BIOINFORMATION, 2022, 18 (02) : 103 - 110
[4] Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review
Bizzarri, Mariano
Monti, Noemi
Piombarolo, Aurora
Angeloni, Antonio
Verna, Roberto
NUTRIENTS, 2023, 15 (08)
[5] Myo-inositol/D-chiro-inositol metabolism in HIV lipodystrophy syndrome
Placek, J
Palmer, M
Currier, J
Vasquez, G
ANTIVIRAL THERAPY, 2004, 9 (06) : L54 - L54
[6] D-Chiro-Inositol treatment in patients with polycystic ovary syndrome
Ciotta, L.
Stracquadanio, M.
Pagano, I.
Formuso, C.
Di Leo, S.
Cianci, A.
GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2012, 34 (01): : 145 - 148
[7] Metabolic and hormonal effects of a combined Myo-inositol and D-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS)
Januszewski, Marcin
Issat, Tadeusz
Jakimiuk, Alicja A.
Santor-Zaczynska, Malgorzata
Jakimiuk, Artur J.
GINEKOLOGIA POLSKA, 2019, 90 (01) : 7 - 10
[8] Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model
Bevilacqua, Arturo
Dragotto, Jessica
Giuliani, Alessandro
Bizzarri, Mariano
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (06) : 9387 - 9398
[9] Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome who undergo ICSI
Llaneza, P.
Aragon, M.
Maldonado, V.
Lorente, J.
Bravo, M. J.
Fonolla, J.
Diaz, M. P.
Olivares, M.
Mendoza, N.
HUMAN REPRODUCTION, 2018, 33 : 436 - 436
[10] From Myo-inositol to D-chiro-inositol molecular pathways
Kiani, A. K.
Paolacci, S.
Calogero, A. E.
Cannarella, R.
Di Renzo, G. C.
Gerli, S.
Della Morte, C.
Busetto, G. M.
De Berardinis, E.
Del Giudice, F.
Stuppia, L.
Facchinetti, F.
Dinicola, S.
Bertelli, M.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (05) : 2390 - 2402

← 1 2 3 4 5 →